Long-awaited Theranos data shows irregularities that could affect care

Ars Technica » Scientific Method 2016-03-29

Founder and CEO of Theranos, Elizabeth Holmes at TEDMED 2014. (credit: https://www.youtube.com/watch?v=dBvzKp0AERE)

Finger-prick blood test results from Theranos, Inc., the beleaguered medical start-up once valued at $9 billion, had more irregularities than those from the top two clinical laboratory testing services, LabCorp and Quest Diagnostics, according to a new study.

Though Theranos’ results mostly fell in line with those from the other labs, researchers say that some of the discrepancies could lead to additional testing and medical costs, or incorrectly sway medical decisions.

The results, published in The Journal of Clinical Investigation, are the first published, peer-reviewed data on the company’s finger-prick blood tests.

Read 11 remaining paragraphs | Comments